Baritab™ 2 Tablet: Each film-coated tablet contains Baricitinib INN 2 mg.
Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulate these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.
The recommended dose of Baricitinib is 2 mg once daily. It may be used as monotherapy or in combination with Methotrexate or other DMARDs. Baricitinib can be given orally with or without food.
Strong OAT3 Inhibitors: Baricitinib exposure is increased when it is co-administered with strong OAT3 inhibitors (such as probenecid). Other JAK Inhibitors or Biologic DMARDs: Baricitinib has not been studied in.
combination with other JAK inhibitors or with biologic DMARDS.
Baricitinib is contraindicated during pregnancy. Lactation: No information is available on the presence of Baricitinib in human milk. Pediatric Use: The safety and effectiveness of Baricitinib in pediatric patients have not been established. Geriatric Use: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Hepatic Impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Renal impairment: Baricitinib is not recommended for use in patients with estimated GFR of less than 60 mL/min/I .73 m2.
To be dispensed only by the prescription of a registered physician.
Store at or below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.